Capricor Therapeutics (CAPR) Research & Development (2010 - 2026)

Capricor Therapeutics' Research & Development history runs 17 years deep, the most recent figure standing at $27.4 million for Q1 2026.

• In Q1 2026, Research & Development rose 44.73% year-over-year to $27.4 million; the TTM figure through Mar 2026 stood at $92.9 million (up 60.72% YoY), while the FY2025 annual figure was $84.5 million, up 69.02% from the prior year.
• Research & Development for Q1 2026 stood at $27.4 million, up from $23.2 million in the prior quarter.
• The five-year high for Research & Development was $27.4 million in Q1 2026, with the low at $5.0 million in Q2 2022.
• The 5-year median for Research & Development is $11.1 million (2024), against an average of $12.9 million.
• The sharpest annual moves came in 2022 and 2024: Research & Development soared 120.17% in 2022, then climbed 17.74% in 2024.
• Capricor Therapeutics' Research & Development stood at $6.2 million in 2022, then surged by 60.45% to $9.9 million in 2023, then soared by 46.45% to $14.6 million in 2024, then soared by 58.94% to $23.2 million in 2025, then gained by 18.24% to $27.4 million in 2026.
• Business Quant data shows CAPR's Research & Development at $27.4 million in Q1 2026, $23.2 million in Q4 2025, and $20.4 million in Q3 2025.